Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells

Table 2 Clinicopathological features of insulin-like growth factor-1 receptor and P-glyco protein expression in hepatocellular carcinoma tissues

Group	n	IGF-IR			P-gp
		Pos. n (%)	χ2 value	P value	Pos. n (%)	χ2 value	P value
Sex
Male	78	73 (93.6)	0.288	0.591	69 (88.5)	0.811	0.057
Female	15	14 (93.3)			13 (86.7)
Age
≤ 50 yr	68	63(92.6)	0.012	0.914	59 (86.8)	1.611	0.204
> 50 yr	25	24(96.0)			23 (92.0)
HBsAg
Positive	60	60 (100)	8.844	0.003	58 (96.6)	9.517	0.002
Negative	33	27 (81.8)			24 (72.7)
AFP
≤ 400 μg/L	59	55 (93.2)	0.104	0.747	51 (86.4)	0.154	0.695
> 400 μg/L	34	32 (94.1)			31 (91.2)
Tumor diameter
≤ 5.0 cm	71	67 (94.4)	3.550	0.060	63 (88.7)	3.208	0.073
> 5.0 cm	22	20 (90.9)			19 (86.4)
Differentiation
Well	21	17 (81.0)	4.201	0.040	16 (76.2)	1.484	0.223
Middle	49	47 (95.9)			43 (87.8)
Poor	23	23 (100)	4.819	0.028	23 (100)	6.178	0.022
Cirrhosis
With	66	62 (93.9)	1.014	0.314	58 (87.9)	0.782	0.377
Without	27	25 (92.6)			24 (88.9)
TNM staging
I-II	58	52 (89.7)	2.3461	0.1256	47 (81.0)	6.161	0.013
III-IV	35	35 (100)			35 (100)
Vascular invasion
With	36	35 (97.2)	25.363	< 0.001	36 (100)	24.158	< 0.001
Without	57	42 (73.7)			46 (80.7)
Tumor number
One	74	69 (93.2)	0.082	0.774	65 (87.8)	0.041	0.841
More	19	18 (94.7)			17 (89.5)

AFP: α-fetoprotein; HBsAg: Hepatitis B virus surface antigen; HCC: Hepatocellular carcinoma; IGF-IR: Insulin-like growth factor-1 receptor; TNM: Tumor-node-metastasis.